KPCM
PPH icon

Kings Point Capital Management’s VanEck Pharmaceutical ETF PPH Stock Holding History

Kings Point Capital Management’s Portfolio PPH Stock Details PPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$48K Hold
600
– – ﹤0.01% 350
2021
Q4 		$46K Hold
600
– – ﹤0.01% 402
2021
Q3 		$44K Buy
+600
New +$44.8K ﹤0.01% 373

Other funds holding PPH

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $1.03B AUM 36.74% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
OPS
Orion Portfolio Solutions Omaha, Nebraska $10.2B AUM 6.73% 1-Year Est. Return
TPWM
Twelve Points Wealth Management Concord, Massachusetts $455M AUM 19.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.04B AUM 49.7% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IMC Chicago
IMC Chicago Chicago, Illinois $278B AUM 44.93% 1-Year Est. Return

Kings Point Capital Management's PPH Position: Q1 2022 in Review

Kings Point Capital Management held its VanEck Pharmaceutical ETF (PPH) position steady in Q1 2022 at 600 shares worth $48K. The position accounts for ﹤0.01% of the portfolio, ranked #350.

Kings Point Capital Management first reported a position in PPH in Q3 2021 and has held it in 3 quarters since. 75 funds tracked by Wall St. Rank hold PPH as of Q1 2022.

  • Kings Point Capital Management held 600 shares of VanEck Pharmaceutical ETF worth $48K as of Q1 2022.
  • Kings Point Capital Management left its VanEck Pharmaceutical ETF share count unchanged in Q1 2022.
  • VanEck Pharmaceutical ETF made up ﹤0.01% of Kings Point Capital Management's portfolio in Q1 2022, its #350 holding.
  • Kings Point Capital Management first reported a position in VanEck Pharmaceutical ETF in Q3 2021 and has held it in 3 quarters since.
  • 75 funds tracked by Wall St. Rank held VanEck Pharmaceutical ETF as of Q1 2022.

Based on Kings Point Capital Management's 13F filing for Q1 2022, filed 13 May 2022.